Vytrus Biotech receives a valuation of 26.4 million euros according to GVC Gaesco

Vytrus became the second most profitable company on the Spanish stock market in 2022

09 of February of 2023
Save
Vytrus Biotech
Vytrus Biotech

The company specialized in plant stem cell derived active ingredients for the cosmetic industry located in Terrassa, Vytrus Biotech, has received a valuation report from GVC Gaesco Securities that estimates a target price December 2023 of 3,71€/share for the company, equivalent to 26.4 million euros, 10% more than yesterday’s market closing quote.

In the previous review of March 2022, GVC Gaesco issued a Vytrus analysis report that awarded a price of €2.83/share. This update represents an increase of 31% in valuation compared to 2022, maintaining the recommendation of "Buy" the values of the biotechnology.

Albert Jané, COO and co-founder of Vytrus said that "Vytrus is immersed in a process of expansion that we are convinced will consolidate us as a benchmark for innovation and sustainability in the cosmetic sector, generating greater value for our shareholders".

Vytrus became the second most profitable company on the Spanish stock exchange in 2022. The company currently capitalizes more than 24 million euros, an increase of 98% since it debuted in March 2022 in BME Growth, the stock market of SMEs. This positions it as the second most profitable company in 2022 of the entire Spanish market.

The biotech debuted at BME Growth last March 2022, at a price of 1.72 €, after a technical listing and became the most successful exit of the year in the SME stock market.

In the first half of 2022 Vytrus obtained revenues of 2 million euros, 51% more than in 2021 and obtained an EBITDA of 0.86 million euros, 62% more.